Tagraxofusp

  • Biologic
  • Elzonris

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Tagraxofusp: storage and handling

Frozen storage
Stated
Label statement
Store in freezer between -25°C and -15°C (-13°F and 5°F).
Freezing
Not addressed
Room temperature
at or below 25°C (77°F)
Label statement
Thaw vials at room temperature between 15°C and 25°C (59°F and 77°F) prior to preparation [see Dosage and Administration ( 2.3 )] .
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

Within the label's stated room-temperature allowance (at up to 25°C (77°F)). Follow the label's instructions for what to do next.

Entered: 1 day at up to 77°F (25°C).

Thaw vials at room temperature between 15°C and 25°C (59°F and 77°F) prior to preparation [see Dosage and Administration ( 2.3 )] .

If anything else happened to the product, or you are unsure, Contact the manufacturer about this product; the label text ClinDose has does not print a phone number for it.

All storage statements on the label (4)
  • Store in freezer between -25°C and -15°C (-13°F and 5°F).
  • Thaw vials at room temperature between 15°C and 25°C (59°F and 77°F) prior to preparation [see Dosage and Administration ( 2.3 )] .
  • Do not refreeze the vial once thawed.
  • Do not use beyond expiration date on container.

FDA label version 11, effective December 9, 2024. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

No Part D formulary in the CMS files (2026Q3) lists this drug. It may be covered under Part B or not covered.

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.